Related Experiment Video
Updated: May 2, 2026

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation
Published on: January 29, 2019
Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis
Kentaro Watanabe1, Noriaki Shimada1, Motoko Kanzaki1
1Department of Nephrology, Kurashiki Central Hospital, Japan.
Abstract:
An underestimated side effect of rituximab is late-onset neutropenia (R-LON), which often resolves spontaneously and rarely results in a severe infection. We herein report a case of febrile neutropenia due to R-LON in a 91-year-old woman with renal failure who was treated with rituximab to induce remission of myeloperoxidase antineutrophil cytoplasmic antibodies-associated vasculitis. Fifty-four days after the last rituximab administration, the patient was hospitalized for febrile neutropenia due to R-LON, which improved with granulocyte colony-stimulating factor and antibiotics. Although R-LON may resolve spontaneously and remain unnoticed, it can cause severe infections in the elderly and patients with renal failure.
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management

